As a potent chemotherapeutic agent, doxorubicin (DOX) is widely used for the treatment of a
variety of cancers However, its clinical utility is limited by dose-dependent cardiotoxicity, and …

Cardiovascular diseases (CVDs) are the leading causes of death worldwide, and defects in
mitochondrial function contribute largely to the occurrence of CVDs. Recent studies suggest …

The dose-dependent toxicity to cardiomyocytes has been well recognized as a central
characteristic of doxorubicin (DOX)-induced cardiotoxicity (DIC), however, the pathogenesis …

Enhancing mitochondrial biogenesis and reducing mitochondrial oxidative stress have
emerged as crucial therapeutic strategies to ameliorate diabetic myocardial …

Doxorubicin (Dox) is widely used in chemotherapy regimens for several malignant
conditions. Unfortunately, cumulative and irreversible cardiotoxicity of Dox is the most …

Background Doxorubicin (DOX) is among the most widely employed antitumor agents,
although its clinical applications have been largely hindered by severe cardiotoxicity. Earlier …

Anthracyclines is an effective chemotherapeutic treatment used for many types of cancer.
However, high cumulative dosage of anthracyclines leads to cardiac toxicity and heart …

Doxorubicin (DOX) is a chemotherapeutic agent effective in the treatment of many cancers.
However, cardiac dysfunction caused by DOX limits its clinical use. DOX is believed to be …

Nanoparticle-based systems explore not only the delivery efficacy of drugs or contrast
agents, but also additional capabilities like reducing the systemic toxicity, especially during …

Congestive heart failure is one of the leading causes of disability in long-term survivors of
cancer. The anthracycline antibiotic doxorubicin (DOX) is used to treat a variety of cancers …